↓ Skip to main content

Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy

Overview of attention for article published in Molecular Cancer, February 2009
Altmetric Badge

Mentioned by

wikipedia
4 Wikipedia pages

Citations

dimensions_citation
142 Dimensions

Readers on

mendeley
168 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy
Published in
Molecular Cancer, February 2009
DOI 10.1186/1476-4598-8-8
Pubmed ID
Authors

Yingmei Wang, Ping Ji, Jinsong Liu, Russell R Broaddus, Fengxia Xue, Wei Zhang

Abstract

In eukaryotic cells, control mechanisms have developed that restrain cell-cycle transitions in response to stress. These regulatory pathways are termed cell-cycle checkpoints. The G(2)/M checkpoint prevents cells from entering mitosis when DNA is damaged in order to afford these cells an opportunity to repair the damaged DNA before propagating genetic defects to the daughter cells. If the damage is irreparable, checkpoint signaling might activate pathways that lead to apoptosis. Since alteration of cell-cycle control is a hallmark of tumorigenesis, cell-cycle regulators represent potential targets for therapy. The centrosome has recently come into focus as a critical cellular organelle that integrates G(2)/M checkpoint control and repairs signals in response to DNA damage. A growing number of G(2)/M checkpoint regulators have been found in the centrosome, suggesting that centrosome has an important role in G(2)/M checkpoint function. In this review, we discuss centrosome-associated regulators of the G(2)/M checkpoint, the dysregulation of this checkpoint in cancer, and potential candidate targets for cancer therapy.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 168 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 2%
Germany 2 1%
France 1 <1%
United Kingdom 1 <1%
India 1 <1%
Singapore 1 <1%
Canada 1 <1%
Unknown 157 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 39 23%
Researcher 30 18%
Student > Master 22 13%
Student > Bachelor 18 11%
Student > Doctoral Student 7 4%
Other 20 12%
Unknown 32 19%
Readers by discipline Count As %
Agricultural and Biological Sciences 71 42%
Biochemistry, Genetics and Molecular Biology 38 23%
Medicine and Dentistry 16 10%
Engineering 4 2%
Chemistry 4 2%
Other 3 2%
Unknown 32 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2023.
All research outputs
#7,730,464
of 23,510,717 outputs
Outputs from Molecular Cancer
#575
of 1,779 outputs
Outputs of similar age
#51,058
of 175,320 outputs
Outputs of similar age from Molecular Cancer
#7
of 21 outputs
Altmetric has tracked 23,510,717 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,779 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 175,320 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.